Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Should You Sell?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) gapped down prior to trading on Thursday. The stock had previously closed at $2.55, but opened at $2.24. Pacific Biosciences of California shares last traded at $2.6580, with a volume of 2,507,690 shares.

Trending Headlines about Pacific Biosciences of California

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: For Q3 2026, PacBio reported a loss of $0.11 per share, better than the $0.13 loss analysts expected, while revenue of $40.56 million exceeded the $39.31 million consensus estimate. Zacks Q3 earnings report
• Positive Sentiment: A Q3 analysis pointed to clinical adoption and AI partnerships as contributors to steady growth, suggesting potential longer-term demand opportunities. Q3 clinical adoption and AI partnerships analysis
• Neutral Sentiment: PacBio narrowed its 2026 revenue guidance to $155 million–$160 million. A tighter range provides an updated outlook, but the article does not specify whether it represents a change in expected performance. Revenue guidance and cash-flow target
• Negative Sentiment: The company still posted a quarterly loss, and management is targeting cash-flow breakeven only in 2028, underscoring the time and execution required to reach sustainable finances. Cash-flow breakeven outlook

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PACB. Wall Street Zen downgraded Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Piper Sandler reiterated a “neutral” rating and set a $3.00 price objective (up from $2.00) on shares of Pacific Biosciences of California in a research note on Thursday. UBS Group started coverage on shares of Pacific Biosciences of California in a report on Wednesday, September 9th. They set a “neutral” rating and a $1.35 price objective on the stock. Finally, Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Pacific Biosciences of California has a consensus rating of “Reduce” and an average price target of $1.96.

Pacific Biosciences of California Stock Down 2.6%

The stock has a 50-day moving average of $1.89 and a 200 day moving average of $1.62. The stock has a market cap of $771.79 million, a PE ratio of -5.78 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $40.56 million during the quarter, compared to the consensus estimate of $39.31 million. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. Research analysts forecast that Pacific Biosciences of California, Inc. will post -0.52 EPS for the current fiscal year.

Insider Buying and Selling at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Mark Van Oene sold 26,911 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1.13, for a total transaction of $30,409.43. Following the transaction, the insider owned 2,705,853 shares of the company’s stock, valued at approximately $3,057,613.89. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James Gibson, II sold 661,815 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the sale, the insider directly owned 1,083,848 shares of the company’s stock, valued at $3,370,767.28. The trade was a 37.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Pacific Biosciences of California

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PACB. BlackRock Inc. purchased a new stake in shares of Pacific Biosciences of California during the second quarter worth approximately $54,330,000. Bank of America Corp DE acquired a new position in Pacific Biosciences of California in the 2nd quarter valued at $2,265,000. Hhlr Advisors LTD. purchased a new stake in shares of Pacific Biosciences of California in the second quarter valued at about $1,544,000. Dimensional Fund Advisors LP boosted its holdings in shares of Pacific Biosciences of California by 177.9% in the first quarter. Dimensional Fund Advisors LP now owns 899,550 shares of the biotechnology company’s stock valued at $1,187,000 after acquiring an additional 575,801 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Pacific Biosciences of California during the second quarter worth about $1,290,000.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.